My wife and I are taking some time off in New Mexico this week, so I did not conduct one of my usual video interviews. However, I did have an interesting phone call with my friend Peter Foti that I would like to share with you.

Those of you involved in nuclear medicine are already familiar with the concept of theranostics. It is a rapidly evolving field where a diagnostic radiopharmaceutical is combined with a therapeutic radiopharmaceutical to achieve a kind of personalized medicine that is tailored to the patient at the cellular level.

What fewer of you may be familiar with, is Actinium-225, and the potential it holds for theranostic applications and the treatment of cancer patients:


If you are interested in learning more about Actinium, I encourage you to check out a few of these articles we have written, and press releases we have shared on our site:

• TerraPower and Cardinal Health announce manufacturing and distribution agreement for Actinium-225
• New radionuclide enables PET imaging of targeted alpha cancer therapies
• BWXT Medical and Bayer AG enter into agreement for development and production of Actinium-225
• IBA and SCK CEN join forces to enable production of Actinium-225
• NorthStar and POINT Biopharma sign therapeutic radioisotope Ac-225 supply agreement